PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicityVikram R. Juneja, Arlene H. Sharpe|The Journal of Experimental Medicine|2017Cited by 872
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutationsJaewon Choi, Vikram R. Juneja, Daniel Rothenberg et al.|Cell Reports Methods|2021Cited by 65
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S.W. Borgers, Marit M. van Buuren, Divya Lenkala et al.|Nature Medicine|2025Cited by 40
Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoveryBrandon Conn, Vikram R. Juneja, Christina Yee et al.|Cell Reports Methods|2025Cited by 5